Insights
Search Results
Client Highlights
4.17.26
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
Client Highlights
3.04.25
Wilson Sonsini Advises WuXi AppTec on Sale of U.S. Medical Device Testing Operations to NAMSA
On March 3, 2025, WuXi AppTec announced that it had completed the sale of its U.S. medical device testing operations to NAMSA. Wilson Sonsini is pleased to have represented WuXi AppTec throughout this transaction.
Client Highlights
1.21.25
Wilson Sonsini Advises WuXi AppTec on Sale of Its U.S. Medical Device Testing Operations to NAMSA
On January 17, 2025, WuXi AppTec, a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology, and medical device industries, announced that it has entered into a definitive agreement to sell its U.S. medical device testing operations to NAMSA, a Toledo, Ohio-based MedTech testing, clinical, and regulatory consulting firm. Under the agreement, NAMSA will acquire WuXi AppTec’s medical device testing facilities in Minnesota and Georgia. Wilson Sonsini Goodrich & Rosati advised WuXi AppTec on the transaction.
Client Highlights
8.09.24
Wilson Sonsini Advises Recursion on Definitive Agreement with Exscientia
On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.
Bylined Articles
4.22.24
The Blake Brief: A Hitchhiker’s Guide to Patent Law in Outer Space
SatMagazine’s latest Blake Brief article, titled "A Hitchhiker’s Guide to Patent Law in Outer Space" and authored by Curt Blake, John Wehrli, Peter Bratton, Magnus Gan, James Dunlop, and Matthew Fleming, discusses the value of conducting pharmaceutical research and development in space. The article specifically examines Merck's development of "space crystals" for its blockbuster Keytruda antibody drug and suggests that future commercial space treaties should be flexible to navigate the questions and complexities around patenting inventions developed in space.
Client Highlights
3.21.24
Wilson Sonsini Advises LENZ Therapeutics on Completed Merger with Graphite Bio
On March 21, 2024, LENZ Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop that has been shown to improve near vision in people with presbyopia, announced the completion of its previously announced merger with Graphite Bio, Inc. The new combined company will operate under the name LENZ Therapeutics, Inc. and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. Wilson Sonsini Goodrich & Rosati advised LENZ Therapeutics on the transaction.
Client Highlights
11.15.23
Wilson Sonsini Represents LENZ Therapeutics in Merger with Graphite Bio
On November 15, 2023, LENZ Therapeutics, a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision, and Graphite Bio, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over the age of 45. The combined company is expected to trade on Nasdaq under the ticker symbol “LENZ.” Wilson Sonsini Goodrich & Rosati is representing LENZ Therapeutics in the transaction.